跳至主要内容
临床试验/DRKS00008579
DRKS00008579招募中不适用

Follow-up investigation of former patients of a rehabilitation center (Leppermühle) with the diagnosis of adolescent schizophrenia - Leppermühle catamnesis

niversitätsklinikum Freiburg, Klinik für Psychiatrie, Psychotherapie und Psychosomatik im Kindes- und Jugendalter0 个研究点目标入组 105 人开始时间: 2015年7月13日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
105

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 65 Years(—)
性别
All

入选标准

  • children and Youngsters suffering from a schizophrenic psychosis, treated in the period from the 01.01.2002 to the 31.12.2004 in the child and youth home Leppermühle.

排除标准

  • F20.6. Schizophrenia simplex, because the reliability and validity of this diagnosis is discussed very controverse.

研究者

发起方
niversitätsklinikum Freiburg, Klinik für Psychiatrie, Psychotherapie und Psychosomatik im Kindes- und Jugendalter

相似试验

已完成
不适用
It is the study for analysis of patients of carcinoma esophagus and gastroesophageal junction who have received chemotherapy before.
CTRI/2014/08/004839ot applicable31
招募中
1 期
ong-Term Follow-Up of TX200-TR101 (STEADFAST Long Term)Kidney Transplant RejectionMedDRA version: 21.1Level: LLTClassification code: 10050436Term: Prophylaxis against renal transplant rejection Class: 10042613
CTIS2024-512580-31-00Sangamo Therapeutics France30
尚未招募
不适用
Outcomes following a Multimodal Pain Protocol in Total Knee ArthroplastyTotal knee arthroplasty post operative pain and mobilitySurgery - Other surgeryMusculoskeletal - Osteoarthritis
ACTRN12612000343808Dr Gerald Yeo100
尚未招募
不适用
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (TX200-TR101) in a prior clinical study.Renal transplant rejectionAllograft rejection1002766510029149
NL-OMON56013Sangamo Therapeutics France SAS8
进行中(未招募)
1 期
ong-Term Follow-Up of Patients who have received an Autologous Antigen-Specific Chimeric Antigen Receptor T Regulatory Cell Therapy (CAR- Treg therapy, TX200-TR101) in a prior clinical study.Prevention of immune mediated allograft rejection in patients with end-stage renal disease (ESRD) who are tissue typed as HLA-A*02 negative and have received a kidney transplant from an HLA-A*02 positive living donor.MedDRA version: 21.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 10042613 - Surgical and medical procedures
EUCTR2022-002440-40-DESangamo Therapeutics France SAS15
Follow-up investigation of former patients of a... | 临床试验